Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm

Circulation Research

Volumn 117, Issue 2, 2015, Pages 129-141

  Liu, Zhenjie ^a,c   Morgan, Stephanie ^a   Ren, Jun ^a   Wang, Qiwei ^a   Annis, Douglas S ^a   Mosher, Deane F ^a   Zhang, Jing ^b   Sorenson, Christine M ^a   Sheibani, Nader ^a   Liu, Bo ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

abdominal aortic aneurysm; inflammation; monocytes

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; SMAD3 PROTEIN; THROMBOSPONDIN 1; ANGIOTENSIN II; APOLIPOPROTEIN E; CALCIUM PHOSPHATE; PANCREATIC ELASTASE; RECOMBINANT PROTEIN;

ABDOMINAL AORTA ANEURYSM; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA WALL; ARTICLE; BLOOD VESSEL WALL; BONE MARROW DERIVED MONONUCLEAR CELL; CELL ADHESION; CELL INFILTRATION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATORY CELL; MALE; MONOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PATHOGENESIS; PERITONEUM MACROPHAGE; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUNICA MEDIA; UPREGULATION; VASCULITIS; ABDOMINAL AORTA; ANIMAL; AORTIC ANEURYSM, ABDOMINAL; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL LINE; CELL MOTION; COMPARATIVE STUDY; DEFICIENCY; DISEASE MODEL; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION CHIMERA; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; BONE MARROW TRANSPLANTATION; CALCIUM PHOSPHATES; CELL LINE; CELL MOVEMENT; DISEASE MODELS, ANIMAL; INFLAMMATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; PANCREATIC ELASTASE; RADIATION CHIMERA; RECOMBINANT PROTEINS; THROMBOSPONDIN 1; UP-REGULATION;

EID: 84937677630     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.305262     Document Type: Article

References (76)

1. Diehm N, Dick F, Schaffner T, Schmidli J, Kalka C, Di Santo S, Voelzmann J, Baumgartner I. Novel insight into the pathobiology of abdominal aortic aneurysm and potential future treatment concepts. Prog Cardiovasc Dis. 2007; 50: 209-217. doi: 10.1016/j.pcad.2007.05.001
2. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol. 2011; 8: 92-102. doi: 10.1038/nrcardio.2010.180
3. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation. 2008; 117: 1883-1889. doi: 10.1161/CIRCULATIONAHA.107.735274
4. Brewster DC, Cronenwett JL, Hallett JW Jr, Johnston KW, Krupski WC, Matsumura JS; Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg. 2003; 37: 1106-1117. doi: 10.1067/mva.2003.363
5. Nordon IM, Hinchliffe RJ, Holt PJ, Loftus IM, Thompson MM. Review of current theories for abdominal aortic aneurysm pathogenesis. Vascular. 2009; 17: 253-263
6. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004; 24: 429-434. doi: 10.1161/01. ATV.0000118013.72016.ea
7. Rateri DL, Howatt DA, Moorleghen JJ, Charnigo R, Cassis LA, Daugherty A. Prolonged infusion of angiotensin II in apoE(-/-) mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am J Pathol. 2011; 179: 1542-1548. doi: 10.1016/j. ajpath.2011.05.049
8. Sun J, Sukhova GK, Yang M, Wolters PJ, MacFarlane LA, Libby P, Sun C, Zhang Y, Liu J, Ennis TL, Knispel R, Xiong W, Thompson RW, Baxter BT, Shi GP. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest. 2007; 117: 3359-3368. doi: 10.1172/JCI31311
9. Curci JA. Digging in the soil of the aorta to understand the growth of abdominal aortic aneurysms. Vascular. 2009; 17(suppl 1): S21-S29
10. Zhang L, Li HY, Li H, Zhao J, Su L, Zhang Y, Zhang SL, Miao JY. Lipopolysaccharide activated phosphatidylcholine-specific phospholipase C and induced IL-8 and MCP-1 production in vascular endothelial cells. J Cell Physiol. 2011; 226: 1694-1701. doi: 10.1002/jcp.22500
11. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002; 110: 625-632. doi: 10.1172/JCI15334
12. Zhang T, Xu J, Li D, Chen J, Shen X, Xu F, Teng F, Deng Y, Ma H, Zhang L, Zhang G, Zhang Z, Wu W, Liu X, Yang M, Jiang B, Guo D. Salvianolic acid a, a matrix metalloproteinase-9 inhibitor of salvia miltiorrhiza, attenuates aortic aneurysm formation in apolipoprotein e-deficient mice. Phytomedicine. 2014; 21: 1137-1145. doi: 10.1016/j. phymed.2014.05.003
13. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000; 105: 1641-1649. doi: 10.1172/JCI8931
14. Deguchi JO, Huang H, Libby P, Aikawa E, Whittaker P, Sylvan J, Lee RT, Aikawa M. Genetically engineered resistance for MMP collagenases promotes abdominal aortic aneurysm formation in mice infused with angiotensin II. Lab Invest. 2009; 89: 315-326. doi: 10.1038/labinvest.2008.167
15. Meijer CA, Stijnen T, Wasser MN, Hamming JF, van Bockel JH, Lindeman JH; Pharmaceutical Aneurysm Stabilisation Trial Study Group. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med. 2013; 159: 815-823
16. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr, Kent KC, Upchurch GR Jr, Chaikof EL, Mills JL, Fleckten B, Longo GM, Lee JK, Thompson RW. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg. 2002; 36: 1-12
17. Aziz F, Kuivaniemi H. Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm. Ann Vasc Surg. 2007; 21: 392-401. doi: 10.1016/j.avsg.2006.11.001
18. Lohoefer F, Reeps C, Lipp C, Rudelius M, Haertl F, Matevossian E, Zernecke A, Eckstein HH, Pelisek J. Quantitative expression and localization of cysteine and aspartic proteases in human abdominal aortic aneurysms. Exp Mol Med. 2014; 46: e95. doi: 10.1038/emm.2014.20
19. Qin Y, Cao X, Yang Y, Shi GP. Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms. Future Cardiol. 2013; 9: 89-103. doi: 10.2217/fca.12.71
20. Golledge AL, Walker P, Norman PE, Golledge J. A systematic review of studies examining inflammation associated cytokines in human abdominal aortic aneurysm samples. Dis Markers. 2009; 26: 181-188. doi: 10.3233/DMA-2009-0629
21. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation. 2008; 118: 2382-2392. doi: 10.1161/CIRCULATIONAHA.108.802074
22. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006; 26: 987-994. doi: 10.1161/01.ATV.0000214999.12921.4f
23. Eliason JL, Hannawa KK, Ailawadi G, Sinha I, Ford JW, Deogracias MP, Roelofs KJ, Woodrum DT, Ennis TL, Henke PK, Stanley JC, Thompson RW, Upchurch GR Jr. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation. 2005; 112: 232-240. doi: 10.1161/CIRCULATIONAHA.104.517391
24. Sun J, Sukhova GK, Yang M, Wolters PJ, MacFarlane LA, Libby P, Sun C, Zhang Y, Liu J, Ennis TL, Knispel R, Xiong W, Thompson RW, Baxter BT, Shi GP. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest. 2007; 117: 3359-3368. doi: 10.1172/JCI31311
25. Michineau S, Franck G, Wagner-Ballon O, Dai J, Allaire E, Gervais M. Chemokine (C-X-C motif) receptor 4 blockade by AMD3100 inhibits experimental abdominal aortic aneurysm expansion through anti-inflammatory effects. Arterioscler Thromb Vasc Biol. 2014; 34: 1747-1755. doi: 10.1161/ATVBAHA.114.303913
26. Adams JC, Lawler J. The thrombospondins. Cold Spring Harb Perspect Biol. 2011; 3: a009712. doi: 10.1101/cshperspect.a009712
27. Talme T, Bergdahl E, Sundqvist KG. Regulation of T-lymphocyte motility, adhesion and de-adhesion by a cell surface mechanism directed by low density lipoprotein receptor-related protein 1 and endogenous thrombospondin-1. Immunology. 2014; 142: 176-192
28. Scheef EA, Sorenson CM, Sheibani N. Attenuation of proliferation and migration of retinal pericytes in the absence of thrombospondin-1. Am J Physiol Cell Physiol. 2009; 296: C724-C734. doi: 10.1152/ajpcell.00409.2008
29. Daniel C, Schaub K, Amann K, Lawler J, Hugo C. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes. 2007; 56: 2982-2989. doi: 10.2337/db07-0551
30. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol. 1993; 122: 923-932
31. Lopez-Dee Z, Pidcock K, Gutierrez LS. Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm. 2011; 2011: 296069. doi: 10.1155/2011/296069
32. Rico MC, Manns JM, Driban JB, Uknis AB, Kunapuli SP, Dela Cadena RA. Thrombospondin-1 and transforming growth factor beta are pro-inflammatory molecules in rheumatoid arthritis. Transl Res. 2008; 152: 95-98. doi: 10.1016/j.trsl.2008.06.002
33. Moura R, Tjwa M, Vandervoort P, Van Kerckhoven S, Holvoet P, Hoylaerts MF. Thrombospondin-1 deficiency accelerates atherosclerotic plaque maturation in ApoE-/-mice. Circ Res. 2008; 103: 1181-1189. doi: 10.1161/CIRCRESAHA.108.185645
34. Li Y, Tong X, Rumala C, Clemons K, Wang S. Thrombospondin1 deficiency reduces obesity-associated inflammation and improves insulin sensitivity in a diet-induced obese mouse model. PLoS One. 2011; 6: e26656. doi: 10.1371/journal.pone.0026656
35. Csányi G, Yao M, Rodríguez AI, Al Ghouleh I, Sharifi-Sanjani M, Frazziano G, Huang X, Kelley EE, Isenberg JS, Pagano PJ. Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol. 2012; 32: 2966-2973. doi: 10.1161/ATVBAHA.112.300031
36. Ng TF, Turpie B, Masli S. Thrombospondin-1-mediated regulation of microglia activation after retinal injury. Invest Ophthalmol Vis Sci. 2009; 50: 5472-5478. doi: 10.1167/iovs.08-2877
37. Masli S, Vega JL. Ocular immune privilege sites. Methods Mol Biol. 2011; 677: 499-458. doi: 10.1007/978-1-60761-869-0.28
38. Favier J, Germain S, Emmerich J, Corvol P, Gasc JM. Critical overexpression of thrombospondin 1 in chronic leg ischaemia. J Pathol. 2005; 207: 358-366. doi: 10.1002/path.1833
39. Smadja DM, d'Audigier C, Bièche I, et al. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler Thromb Vasc Biol. 2011; 31: 551-559. doi: 10.1161/ATVBAHA.110.220624
40. Moxon JV, Padula MP, Clancy P, Emeto TI, Herbert BR, Norman PE, Golledge J. Proteomic analysis of intra-arterial thrombus secretions reveals a negative association of clusterin and thrombospondin-1 with abdominal aortic aneurysm. Atherosclerosis. 2011; 219: 432-439. doi: 10.1016/j.atherosclerosis.2011.08.013
41. Browne PV, Mosher DF, Steinberg MH, Hebbel RP. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol. 1996; 51: 296-301. doi: 10.1002/(SICI)1096-8652(199604)51: 43.0.CO; 2-R
42. Daugherty A, Rateri DL, Charo IF, Owens AP, Howatt DA, Cassis LA. Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/-mice. Clin Sci (Lond). 2010; 118: 681-689. doi: 10.1042/CS20090372
43. Maiellaro K, Taylor WR. The role of the adventitia in vascular inflammation. Cardiovasc Res. 2007; 75: 640-648. doi: 10.1016/j. cardiores.2007.06.023
44. Tieu BC, Lee C, Sun H, Lejeune W, Recinos A III, Ju X, Spratt H, Guo DC, Milewicz D, Tilton RG, Brasier AR. An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J Clin Invest. 2009; 119: 3637-3651. doi: 10.1172/JCI38308
45. de Waard V, Bot I, de Jager SC, Talib S, Egashira K, de Vries MR, Quax PH, Biessen EA, van Berkel TJ. Systemic MCP1/CCR2 blockade and leukocyte specific MCP1/CCR2 inhibition affect aortic aneurysm formation differently. Atherosclerosis. 2010; 211: 84-89. doi: 10.1016/j. atherosclerosis.2010.01.042
46. Yamanouchi D, Morgan S, Stair C, Seedial S, Lengfeld J, Kent KC, Liu B. Accelerated aneurysmal dilation associated with apoptosis and inflammation in a newly developed calcium phosphate rodent abdominal aortic aneurysm model. J Vasc Surg. 2012; 56: 455-461. doi: 10.1016/j. jvs.2012.01.038
47. Sid B, Sartelet H, Bellon G, El Btaouri H, Rath G, Delorme N, Haye B, Martiny L. Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol. 2004; 49: 245-258. doi: 10.1016/j.critrevonc.2003.09.009
48. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 2003; 22: 63-71
49. Yamauchi M, Imajoh-Ohmi S, Shibuya M. Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci. 2007; 98: 1491-1497. doi: 10.1111/j.1349-7006.2007.00534.x
50. Scheef EA. Isolation and characterization of corneal endothelial cells from wild type and thrombospondin-1 deficient mice. Molecular Vision. 2007; 13: 1483-1495
51. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol. 2005; 168: 643-653. doi: 10.1083/jcb.200407060
52. Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 1997; 57: 1735-1742
53. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997; 138: 707-717
54. Stein JJ, Iwuchukwu C, Maier KG, Gahtan V. Thrombospondin-1-induced vascular smooth muscle cell migration and proliferation are functionally dependent on microRNA-21. Surgery. 2014; 155: 228-233. doi: 10.1016/j. surg.2013.08.003
55. Morgan S, Yamanouchi D, Harberg C, Wang Q, Keller M, Si Y, Burlingham W, Seedial S, Lengfeld J, Liu B. Elevated protein kinase C-δ contributes to aneurysm pathogenesis through stimulation of apoptosis and inflammatory signaling. Arterioscler Thromb Vasc Biol. 2012; 32: 2493-2502. doi: 10.1161/ATVBAHA.112.255661
56. Yamanouchi D, Morgan S, Kato K, Lengfeld J, Zhang F, Liu B. Effects of caspase inhibitor on angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2010; 30: 702-707. doi: 10.1161/ATVBAHA.109.200527
57. Kong P, Cavalera M, Frangogiannis NG. The role of thrombospondin (TSP)-1 in obesity and diabetes. Adipocyte. 2014; 3: 81-84. doi: 10.4161/adip.26990
58. Maier KG, Han X, Sadowitz B, Gentile KL, Middleton FA, Gahtan V. Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia. J Vasc Surg. 2010; 51: 1238-1247. doi: 10.1016/j. jvs.2009.11.073
59. Raman P, Krukovets I, Marinic TE, Bornstein P, Stenina OI. Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem. 2007; 282: 5704-5714. doi: 10.1074/jbc.M610965200
60. Isenberg JS, Hyodo F, Matsumoto K-I, Romeo MJ, Abu-Asab M, Tsokos M, Kuppusamy P, Wink DA, Krishna MC, Roberts DD. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. 2007; 109: 1945-1952
61. Frangogiannis NG, Ren G, Dewald O, Zymek P, Haudek S, Koerting A, Winkelmann K, Michael LH, Lawler J, Entman ML. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation. 2005; 111: 2935-2942. doi: 10.1161/CIRCULATIONAHA.104.510354
62. Streit M, Velasco P, Riccardi L, Spencer L, Brown LF, Janes L, Lange-Asschenfeldt B, Yano K, Hawighorst T, Iruela-Arispe L, Detmar M. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J. 2000; 19: 3272-3282. doi: 10.1093/emboj/19.13.3272
63. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest. 1998; 101: 982-992. doi: 10.1172/JCI1684
64. van Den Borne P, Quax PH, Hoefer IE, Pasterkamp G. The multifaceted functions of CXCL10 in cardiovascular disease. Biomed Res Int. 2014; 2014: 893106. doi: 10.1155/2014/893106
65. Subramanian V, Golledge J, Ijaz T, Bruemmer D, Daugherty A. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}. Circ Res. 2010; 107: 953-958. doi: 10.1161/CIRCRESAHA.110.219089
66. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011; 11: 750-761. doi: 10.1038/nri3088
67. Jenkins SJ, Ruckerl D, Thomas GD, Hewitson JP, Duncan S, Brombacher F, Maizels RM, Hume DA, Allen JE. IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1. J Exp Med. 2013; 210: 2477-2491. doi: 10.1084/jem.20121999
68. Gao AG, Frazier WA. Identification of a receptor candidate for the carboxyl-terminal cell binding domain of thrombospondins. J Biol Chem. 1994; 269: 29650-29657
69. Sick E, Jeanne A, Schneider C, Dedieu S, Takeda K, Martiny L. CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br J Pharmacol. 2012; 167: 1415-1430. doi: 10.1111/j.1476-5381.2012.02099.x
70. Yamauchi Y, Kuroki M, Imakiire T, Uno K, Abe H, Beppu R, Yamashita Y, Kuroki M, Shirakusa T. Opposite effects of thrombospondin-1 via CD36 and CD47 on homotypic aggregation of monocytic cells. Matrix Biol. 2002; 21: 441-448
71. Frolova EG, Pluskota E, Krukovets I, Burke T, Drumm C, Smith JD, Blech L, Febbraio M, Bornstein P, Plow EF, Stenina OI. Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circ Res. 2010; 107: 1313-1325. doi: 10.1161/CIRCRESAHA.110.232371
72. Mansfield PJ, Suchard SJ. Thrombospondin promotes chemotaxis and haptotaxis of human peripheral blood monocytes. J Immunol. 1994; 153: 4219-4229
73. Ishibashi M, Egashira K, Zhao Q, Hiasa K, Ohtani K, Ihara Y, Charo IF, Kura S, Tsuzuki T, Takeshita A, Sunagawa K. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol. 2004; 24: e174-e178. doi: 10.1161/01.ATV.0000143384.69170.2d
74. Schubl S, Tsai S, Ryer EJ, Wang C, Hu J, Kent KC, Liu B. Upregulation of protein kinase cdelta in vascular smooth muscle cells promotes inflammation in abdominal aortic aneurysm. J Surg Res. 2009; 153: 181-187. doi: 10.1016/j.jss.2008.04.032
75. Sweetwyne MT, Murphy-Ullrich JE. Thrombospondin1 in tissue repair and fibrosis: TGF-β-dependent and independent mechanisms. Matrix Biol. 2012; 31: 178-186. doi: 10.1016/j.matbio.2012.01.006
76. Krishna SM, Seto SW, Jose RJ, Biros E, Moran CS, Wang Y, Clancy P, Golledge J. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol. 2015; 35: 389-398. doi: 10.1161/ATVBAHA.114.304732